Wednesday - December 25, 2024
Ropes & Gray: Erasca Announces Strategic In-Licensing of RAS Mutation Targeting Oncology Program
May 21, 2024
BOSTON, Massachusetts, May 21 -- Ropes and Gray, a law firm, issued the following news:

Ropes & Gray advised Erasca, Inc., a precision oncology company, in an exclusive license agreement for a pre-clinical RAS mutation targeting program with a potent oral tumor inhibitor, a potential best-in-class pan-RAS molecular glue called ERAS-0015. The transaction was announced on May 16.

Under the license agreement, in exchange for an exclusive license to develop and commerci . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation
Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products